MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.805 -0.045 (-2.43%)
Streaming Delayed Price Updated: 3:32 PM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Preview: Lineage Cell Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
EXCLUSIVE: Lineage Cell Inks Exclusive Agreement For Novel Cell-Based Therapies With Potential In Neurology ↗
Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive option and license agreement with Eterna Therapeutics Inc for beta 2 microglobulin (B2M)-deficient induced pluripotent stem cell... 
Via Benzinga
News headline image
Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies ↗
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development. 
Via Benzinga
News headline image
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
News headline image
Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Preview: Lineage Cell Therapeutics ↗
Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-11-10. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer
From Lineage Cell Therapeutics, Inc.
Via Business Wire
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems. 
Via TheNewswire.com
News headline image
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
By David Willey, Benzinga 
Via News Direct
News headline image
121 Stocks That Hit Their 52-Week Low ↗
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows. 
Via Benzinga
News headline image
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field ↗
Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems. 
Via Benzinga
News headline image
Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility ↗
Lineage Cell Therapeutics Inc (NYSE: LCTX) has opened a new research and development facility in Carlsbad, California. 
Via Benzinga
News headline image
The Three Best Anti-Aging Stocks to Buy in September ↗
These three anti-aging stocks could see recovery ahead. ATHX, LCTX, and UBX can make great long-term investments 
Via InvestorPlace
News headline image
Lineage Cell Therapeutics Earnings Perspective: Return On Capital Employed ↗
According to data from Benzinga Pro, during Q2, Lineage Cell Therapeutics's (AMEX:LCTX) reported sales totaled $4.55 million. Despite a 4.38% increase in earnings, the company posted a loss of $6.78... 
Via Benzinga
News headline image
Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Recap: Lineage Cell Therapeutics Q2 Earnings ↗
  Lineage Cell Therapeutics (AMEX:LCTX) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story